Skip to Content

Dynavax Technologies Corp DVAX

Morningstar Rating
$12.75 +0.31 (2.49%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

DVAX is trading at a 6% discount.
Price
$12.70
Fair Value
$87.56
Uncertainty
High
1-Star Price
$19.97
5-Star Price
$89.63
Economic Moat
Zhsv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DVAX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$12.44
Day Range
$12.2713.06
52-Week Range
$9.4215.15
Bid/Ask
$12.42 / $12.90
Market Cap
$1.65 Bil
Volume/Avg
3.0 Mil / 1.9 Mil

Key Statistics

Price/Earnings (Normalized)
32.43
Price/Sales
4.64
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
408

Comparables

Valuation

Metric
DVAX
NWBO
VIR
Price/Earnings (Normalized)
32.43
Price/Book Value
2.670.79
Price/Sales
4.64301.2625.43
Price/Cash Flow
13.24
Price/Earnings
DVAX
NWBO
VIR

Financial Strength

Metric
DVAX
NWBO
VIR
Quick Ratio
14.140.1410.28
Current Ratio
15.400.1710.72
Interest Coverage
6.32−12.79
Quick Ratio
DVAX
NWBO
VIR

Profitability

Metric
DVAX
NWBO
VIR
Return on Assets (Normalized)
13.42%−175.05%−19.21%
Return on Equity (Normalized)
23.09%−24.70%
Return on Invested Capital (Normalized)
13.48%−26.79%
Return on Assets
DVAX
NWBO
VIR
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AFmd$90.3 Bil
MKKGY
Merck KGaA ADRVwkscks$74.8 Bil
HLN
Haleon PLC ADRQklp$38.3 Bil
VTRS
Viatris IncXxxh$16.2 Bil
RDY
Dr Reddy's Laboratories Ltd ADRCnht$13.0 Bil
CTLT
Catalent IncXvswbw$10.6 Bil
PRGO
Perrigo Co PLCKwwp$4.4 Bil
CURLF
Curaleaf Holdings IncFpgg$3.9 Bil
PBH
Prestige Consumer Healthcare IncLrmbks$3.5 Bil
GTBIF
Green Thumb Industries IncShqn$3.4 Bil

Sponsor Center